Drug intelligence / Profile preview

CT7 + MAGE-A3 + WT1 mRNA-electroporated Langerhans cells

Development stage: Phase 1
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

This is an autologous cell-based cancer vaccine composed of CD34+ hematopoietic progenitor cell-derived Langerhans-type dendritic cells (LCs) that have been electroporated with messenger RNA (mRNA) encoding three tumor-associated antigens: CT7, MAGE-A3, and Wilms tumor 1 (WT1). The process involves collecting stem cells from the patient for transplantation and using a portion to generate dendritic cells in vitro. These dendritic cells are then loaded with the specified antigen-encoding mRNAs via electroporation. When administered subcutaneously as a vaccine after autologous stem cell transplantation (ASCT), these modified LCs present the encoded antigens to T-cells, aiming to stimulate robust antigen-specific CD4+ and CD8+ T-cell responses against multiple myeloma tumor cells expressing these antigens. The approach is designed to enhance immune surveillance and reduce relapse risk post-transplantation by broadening the anti-tumor immune response[2][3][5].

Other names: autologous CT7/MAGE-A3/WT1 mRNA-electroporated Langerhans-type dendritic cell vaccinetriple antigen-bearing mRNA-electroporated autologous LC vaccine

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on CT7 + MAGE-A3 + WT1 mRNA-electroporated Langerhans cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT7 + MAGE-A3 + WT1 mRNA-electroporated Langerhans cells.

Explore the full profile